Back

Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials

30 August 2026 (10:15 - 10:45)
Organised by: Logo
Congress Presentation Part of: New advancements in targeting atherogenic lipoproteins Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kunal Mahajan

Himachal Heart Institute, Mandi (India)

4 More presentations in this session

Presentation thumbnail
Long-term outcomes of beta-blockers in post-MI patients with mildly reduced or preserved left ventricular ejection fraction: a systematic review and meta-analysis
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia
Doctor K. Dyankov (Sofia, BG)
Abstract Slides
Presentation thumbnail
Preclinical study and evaluation of S016, a novel oral small-molecule PCSK9 inhibitor
Doctor G. Cen (Chengdu - Sichuan, CN)
Abstract Slides
Presentation thumbnail
Efficacy of PCSK9 inhibitors in patients with peripheral artery disease: insights from the AT-TARGET-IT Registry
Doctor M. Di Santo (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
New advancements in targeting atherogenic lipoproteins

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020
thumbnail
Congress Session
The clinical face of familial chylomicronemia syndrome: improving recognition, diagnosis, and management
28 August 2026
thumbnail
Congress Presentation
Comparing coronary artery plaque regression in patients treated with ezetimibe or PCSK9 inhibitors following acute coronary syndrome: a systematic review and meta-analysis
29 August 2025
thumbnail
Congress Presentation
Autoantibodies directed against apolipoprotein-a-1 as a potential contributor to non-alcoholic fatty liver disease
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources